CUBICIN® (daptomycin for injection) has been used in the treatment of more than an estimated 1.1 million patients with serious and sometimes life-threatening infections. Since we began selling CUBICIN in November 2003, it has experienced the most successful I.V. antibiotic launch, in dollar terms, in U.S. history. CUBICIN has generated hundreds of millions of dollars in annual sales that helped propel Cubist into one of the Commonwealth's best-performing firms, as evidenced by being ranked in The Boston Globe’s annual list of the "Top Places to Work" in Massachusetts. Cubist ranked 24th on the medium-sized company list, and the highest-ranked public life sciences company among that same group.
Mass High Tech announced that Cubist was among the top 30 Fastest-Growing Public Technology Companies in New England for 2010. The list was determined by public companies’ sales growth as a percentage over the past five years (relative to 2009 totals). Cubist ranked 13th of the 30 technology companies that made the list and was one of ten pharmaceutical companies, as well as being named to FORTUNE’s List of 100 Fastest-Growing Companies, and once again to Deloitte Technology Fast 500™.